Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study

Annals of the Rheumatic Diseases

Volumn 71, Issue 9, 2012, Pages 1502-1509

  Hanly, John G ^a   Urowitz, Murray B ^b   Su, Li ^c   Gordon, Caroline ^d   Bae, Sang Cheol ^e   Sanchez Guerrero, Jorge ^b   Romero Diaz, Juanita ^f   Wallace, Daniel J ^g   Clarke, Ann E ^h   Ginzler, E M ⁱ   Merrill, Joan T ^j   Isenberg, David A ^k   Rahman, Anisur ^k   Petri, M ^l   Fortin, Paul R ^m   Gladman, D D ^b   Bruce, Ian N ⁿ   Steinsson, Kristjan ^o   Dooley, M A ^p   Khamashta, Munther A ^q   Alarcón, Graciela S ^r   Fessler, Barri J ^r   Ramsey Goldman, Rosalind ^s   Manzi, Susan ^t   Zoma, Asad A ^u   Sturfelt, Gunnar K ^v   Nived, Ola ^v   Aranow, Cynthia ^w   Mackay, Meggan ^w   Ramos Casals, Manuel ^x   Van Vollenhoven, R F ^y   Kalunian, Kenneth C ^z   Ruiz Irastorza, Guillermo ^aa   Lim, Sam ^ab   Kamen, Diane L ^ac   Peschken, Christine A ^ad   Inanc, Murat ^ae   Theriault, Chris ^a   Thompson, Kara ^a   Farewell, Vernon ^c   more..

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MRC BIOSTATISTICS UNIT   (United Kingdom)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e Hanyang University Hospital for Rheumatic Diseases   (South Korea)

^f INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h MONTREAL GENERAL HOSPITAL   (Canada)

ⁱ SUNY Downstate Medical Center   (United States)

^j OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^k UNIVERSITY COLLEGE LONDON   (United Kingdom)

^l JOHNS HOPKINS UNIVERSITY   (United States)

^m LAVAL UNIVERSITY   (Canada)

ⁿ UNIVERSITY OF MANCHESTER   (United Kingdom)

^o LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^p UNIVERSITY OF NORTH CAROLINA   (United States)

^q ST THOMAS HOSPITAL   (United Kingdom)

^r University of Alabama at Birmingham   (United States)

^s NORTHWESTERN UNIVERSITY   (United States)

^t UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^u HAIRMYRES HOSPITAL   (United Kingdom)

^v LUND UNIVERSITY HOSPITAL   (Sweden)

^w FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^x HOSPITAL CLÍNIC   (Spain)

^y KAROLINSKA INSTITUTE   (Sweden)

^z UNIVERSITY OF CALIFORNIA   (United States)

^aa UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^ab EMORY UNIVERSITY   (United States)

^ac MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^ad UNIVERSITY OF MANITOBA   (Canada)

^ae ISTANBUL UNIVERSITY   (Turkey)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIMALARIAL AGENT; BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; GLUTAMATE RECEPTOR 2; IMMUNOSUPPRESSIVE AGENT; LUPUS ANTICOAGULANT;

ADULT; ANTIBODY DETECTION; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; EDUCATIONAL STATUS; ETHNICITY; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGRO; PATIENT ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN DETERMINATION; RISK FACTOR; SEIZURE; SHORT FORM 36; SYSTEMIC LUPUS ERYTHEMATOSUS;

COHORT STUDIES; EPILEPSY; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 84864868783     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-201089     Document Type: Article

References (34)

1. Ainiala H, Loukkola J, Peltola J, et al. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology 2001;57:496-500. (Pubitemid 32757599)
2. Brey RL, Holliday SL, Saklad AR, et al. Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 2002;58:1214-20. (Pubitemid 34411865)
3. Hanly JG, McCurdy G, Fougere L, et al. Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance. J Rheumatol 2004;31:2156-62. (Pubitemid 39453234)
4. Sanna G, Bertolaccini ML, Cuadrado MJ, et al. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol 2003;30:985-92. (Pubitemid 36529618)
5. Sibbitt WL Jr, Brandt JR, Johnson CR, et al. The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus. J Rheumatol 2002;29:1536-42. (Pubitemid 34755624)
6. Hanly JG, Urowitz MB, Sanchez-Guerrero J, et al. Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum 2007;56:265-73. (Pubitemid 46106200)
7. Isenberg D, Ramsey-Goldman R. Systemic Lupus International Collaborating Group - onwards and upwards? Lupus 2006;15:606-7. (Pubitemid 44661749)
8. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
9. Gladman DD, Ibanez D, Urowitz MS. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29:288-91. (Pubitemid 34118775)
10. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363-9. (Pubitemid 26085211)
11. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999;42:599-608.
12. Ainiala H, Hietaharju A, Loukkola J, et al. Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: a population-based evaluation. Arthritis Rheum 2001;45:419-23. (Pubitemid 32979846)
13. Hanly JG, Urowitz MB, Su L, et al. Short-term outcome of neuropsychiatric events in systemic lupus erythematosus upon enrollment into an international inception cohort study. Arthritis Rheum 2008;59:721-9. (Pubitemid 351679549)
14. Hanly JG, Urowitz MB, Jackson D, et al. SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus. Ann Rheum Dis 2011;70:961-7.
15. Thumboo J, Fong KY, Ng TP, et al. Validation of the MOS SF-36 for quality of life assessment of patients with systemic lupus erythematosus in Singapore. J Rheumatol 1999;26:97-102. (Pubitemid 29051403)
16. Merrill JT, Zhang HW, Shen C, et al. Enhancement of protein S anticoagulant function by beta2-glycoprotein I, a major target antigen of antiphospholipid antibodies: beta2-glycoprotein I interferes with binding of protein S to its plasma inhibitor, C4b-binding protein. Thromb Haemost 1999;81:748-57. (Pubitemid 29216562)
17. Merrill JT, Shen C, Gugnani M, et al. High prevalence of antiphospholipid antibodies in patients taking procainamide. J Rheumatol 1997;24:1083-8. (Pubitemid 27250113)
18. Erkan D, Zhang HW, Shriky RC, et al. Dual antibody reactivity to beta2-glycoprotein I and protein S: increased association with thrombotic events in the antiphospholipid syndrome. Lupus 2002;11:215-20. (Pubitemid 34506725)
19. Hanly JG, Urowitz MB, Siannis F, et al. Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study. Arthritis Rheum 2008;58:843-53. (Pubitemid 351364883)
20. Ibañez D, Gladman DD, Urowitz MB. Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE. J Rheumatol 2005;32:824-7. (Pubitemid 40676490)
21. Andrade RM, Alarcón GS, González LA, et al. Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV). Ann Rheum Dis 2008;67:829-34. (Pubitemid 351829384)
22. González-Duarte A, Cantú-Brito CG, Ruano-Calderón L, et al. Clinical description of seizures in patients with systemic lupus erythematosus. Eur Neurol 2008;59:320-3. (Pubitemid 351543133)
23. Jolly M, Mikolaitis RA, Shakoor N, et al. Education, zip code-based annualized household income, and health outcomes in patients with systemic lupus erythematosus. J Rheumatol 2010;37:1150-7.
24. Callahan LF, Pincus T. Associations between clinical status questionnaire scores and formal education level in persons with systemic lupus erythematosus. Arthritis Rheum 1990;33:407-11. (Pubitemid 20109194)
25. Ward MM. Education level and mortality in systemic lupus erythematosus (SLE): evidence of underascertainment of deaths due to SLE in ethnic minorities with low education levels. Arthritis Rheum 2004;51:616-24. (Pubitemid 39056251)
26. Appenzeller S, Cendes F, Costallat LT. Epileptic seizures in systemic lupus erythematosus. Neurology 2004;63:1808-12. (Pubitemid 39532373)
27. Mikdashi J, Krumholz A, Handwerger B. Factors at diagnosis predict subsequent occurrence of seizures in systemic lupus erythematosus. Neurology 2005;64:2102-7. (Pubitemid 40881002)
28. Shah BR, Laupacis A, Hux JE, et al. Propensity score methods gave similar results to traditional regression modeling in observational studies: a systematic review. J Clin Epidemiol 2005;58:550-9. (Pubitemid 40692720)
29. A randomised study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. N Engl J Med 1991;324:150-4.
30. Fessler BJ, Alarcón GS, McGwin G Jr, et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 2005;52:1473-80. (Pubitemid 40663939)
31. Ruiz-Irastorza G, Egurbide MV, Pijoan JI, et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 2006;15:577-83. (Pubitemid 44661744)
32. Alarcón GS, McGwin G, Bertoli AM, et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis 2007;66:1168-72. (Pubitemid 47309732)
33. Shinjo SK, Bonfá E, Wojdyla D, et al. Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum 2010;62:855-62.
34. Bertsias GK, Ioannidis JP, Aringer M, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 2010;69:2074-82.